Arcus Biosciences Inc (NYSE:RCUS) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokers have set a 1-year consensus price target of $21.50 for the company and are forecasting that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also given Arcus Biosciences an industry rank of 92 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Arcus Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, September 19th.
In related news, CEO Terry J. Rosen acquired 9,929 shares of the company’s stock in a transaction on Monday, August 13th. The stock was purchased at an average cost of $11.87 per share, with a total value of $117,857.23. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Terry J. Rosen acquired 28,401 shares of the company’s stock in a transaction on Thursday, August 16th. The stock was bought at an average cost of $12.64 per share, with a total value of $358,988.64. The disclosure for this purchase can be found here. Insiders acquired a total of 85,117 shares of company stock valued at $1,118,707 over the last ninety days.
Several institutional investors have recently bought and sold shares of the company. DAFNA Capital Management LLC acquired a new position in shares of Arcus Biosciences during the 1st quarter worth $116,000. Point72 Asia Hong Kong Ltd acquired a new position in shares of Arcus Biosciences during the 1st quarter worth $118,000. Cubist Systematic Strategies LLC acquired a new position in shares of Arcus Biosciences during the 1st quarter worth $137,000. Zimmer Partners LP acquired a new position in shares of Arcus Biosciences during the 1st quarter worth $154,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of Arcus Biosciences during the 1st quarter worth $154,000. 39.02% of the stock is owned by institutional investors.
NYSE:RCUS traded down $0.09 during mid-day trading on Tuesday, hitting $14.41. 43,600 shares of the stock were exchanged, compared to its average volume of 146,645. Arcus Biosciences has a fifty-two week low of $10.80 and a fifty-two week high of $22.10.
Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Monday, August 6th. The company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.30 million. equities research analysts forecast that Arcus Biosciences will post -1.81 earnings per share for the current year.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
Featured Article: S&P 500 Index
Get a free copy of the Zacks research report on Arcus Biosciences (RCUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com